medRxiv preprint doi: https://doi.org/10.1101/2020.01.22.20018424; this version posted January 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Genome-wide meta-analysis, fine-mapping, and integrative prioritization identify new Alzheimer’s disease risk genes Jeremy Schwartzentruber1,2*, Sarah Cooper2,3, Jimmy Z Liu4, Inigo Barrio-Hernandez1,2, Erica Bello2,3, Natsuhiko Kumasaka3, Toby Johnson5, Karol Estrada6, Daniel J. Gaffney2,3,7, Pedro Beltrao1,2, Andrew Bassett2,3* *Corresponding: Jeremy Schwartzentruber (
[email protected]) Andrew Bassett (
[email protected]) Affiliations: 1. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL- EBI), Wellcome Genome Campus, Cambridge, UK 2. Open Targets, Wellcome Genome Campus, Cambridge, UK 3. Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK 4. Biogen, Cambridge, MA, 02142, USA 5. Target Sciences-R&D, GSK Medicines Research Centre, Stevenage, UK 6. BioMarin Pharmaceutical, San Rafael, CA 94901, USA 7. Genomics Plc, Oxford, OX1 1JD, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.01.22.20018424; this version posted January 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .